Alembic Pharmaceuticals Ltd (APLLTD) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 533573 | NSE: APLLTD | Pharmaceuticals & Drugs | Small Cap

Alembic Pharma Share Price

902 -0.20 -0.02%
as on 05-Dec'25 15:31

Alembic Pharmaceuticals Ltd (APLLTD) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 533573 | NSE: APLLTD | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Alembic Pharma

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Alembic Pharmaceuticals stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
27.95
Market Cap:
17,733.9 Cr.
52-wk low:
725.6
52-wk high:
1,122.4

Is Alembic Pharmaceuticals Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Alembic Pharma: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Alembic Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 65.9%28.9%22.2%22.7%23.3%26.3%11.3%7.4%13.4%13.5%-
Value Creation
Index
3.91.10.60.70.71.0-0.2-0.50.20-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 3,1663,1353,1313,9354,6065,3935,3065,6536,2296,6727,083
Sales YoY Gr.--1%-0.1%25.7%17.1%17.1%-1.6%6.5%10.2%7.1%-
Adj EPS 3821.620.730.245.255.324.817.530.528.232.3
YoY Gr.--43.1%-4.3%46.2%49.6%22.6%-55.2%-29.4%74.3%-7.5%-
BVPS (₹) 84.7100.9117.8144.2170.8257.8266.5222.4245.1264.1270.6
Adj Net
Profit
7154073895698511,088487344600555634
Cash Flow from Ops. 9483293128124491,46355272480388-
Debt/CF from Ops. 0.10.32.31.43.90.31.10.90.513.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 8.6%7.7%7.9%7.1%
Adj EPS -3.2%-9%4.4%-7.5%
BVPS13.5%9.1%-0.3%7.7%
Share Price 2.9% -2.3% 14.8% -17%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
57.723.318.92328.726.39.57.213.111.112.1
Op. Profit
Mgn %
31.819.819.721.826.427.416.512.6151515.9
Net Profit
Mgn %
22.613.112.714.717.919.69.26.19.68.39
Debt to
Equity
0.10.10.30.40.50.10.10.20.10.20
Working Cap
Days
146159194182186181192188174196103
Cash Conv.
Cycle
1626323869708810510212140

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Alembic Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 22.6 32.3
TTM Sales (₹ Cr.) 6,267 7,083
BVPS (₹.) 267.4 270.6
Reserves (₹ Cr.) 5,216 5,280
P/BV 3.37 3.33
PE 39.94 27.95
From the Market
52 Week Low / High (₹) 725.60 / 1122.40
All Time Low / High (₹) 34.00 / 1296.15
Market Cap (₹ Cr.) 17,734
Equity (₹ Cr.) 39.3
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Alembic Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Alembic Pharma - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Alembic Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales3,1663,1353,1313,9354,6065,3935,3065,6536,2296,672
Operating Expenses 2,1612,5202,5163,0793,3923,9134,4324,9455,2965,669
Manufacturing Costs330354315358471491500561561620
Material Costs8248888869931,0391,2571,4461,7091,7151,793
Employee Cost 4735596237479061,0511,1331,1691,4461,562
Other Costs 5347206929819751,1141,3521,5061,5741,693
Operating Profit 1,0056156158561,2141,4808747089331,003
Operating Profit Margin (%) 31.7%19.6%19.7%21.8%26.4%27.4%16.5%12.5%15.0%15.0%
Other Income 93352714875032948
Interest 55318271618505679
Depreciation 7283105115157183287275273279
Exceptional Items 0000-44000013
Profit Before Tax 9365295417491,0001,368625355632707
Tax 2161221201571992531041316125
Profit After Tax 7204074215938011,115521342616582
PAT Margin (%) 22.7%13.0%13.4%15.1%17.4%20.7%9.8%6.1%9.9%8.7%
Adjusted EPS (₹)38.221.421.931.044.058.326.517.431.329.7
Dividend Payout Ratio (%)10%19%18%18%23%24%38%46%35%37%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 1,5971,9022,2202,7193,2195,0675,2384,3704,8185,191
Share Capital 38383838383939393939
Reserves 1,5601,8652,1822,6813,1825,0285,1984,3314,7795,152
Minority Interest000-1-290000-1
Debt114897089281,7472004306364301,196
Long Term Debt005004998872000000
Short Term Debt1148920842986104306364301,196
Trade Payables566501759644626669706680736880
Others Liabilities 3493193766616281,026856378357444
Total Liabilities 2,6262,8114,0644,9526,1926,9617,2306,0646,3417,709

Fixed Assets

Gross Block1,0949501,2421,5232,1322,5452,8403,4683,8754,117
Accumulated Depreciation3861512493645817571,0421,0691,3291,594
Net Fixed Assets 7087999931,1581,5521,7881,7982,3982,5472,524
CWIP 933961,0101,5511,8462,1832,304601524837
Investments 53504249182361189693127
Inventories5706337349671,1881,4861,6101,4751,6442,288
Trade Receivables3503395264898653498071,0461,0251,400
Cash Equivalents 4511609020681106698212790
Others Assets 400434668532643814523364382443
Total Assets 2,6262,8114,0644,9526,1926,9617,2306,0646,3417,709

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 9483293128124491,46355272480388
PBT 9365295417491,0001,368625355632707
Adjustment 708387118278102418488287374
Changes in Working Capital 139-166-181112-593238-367-58-96-921
Tax Paid -197-118-135-166-236-245-123-61-20-71
Cash Flow From Investing Activity -307-486-884-756-732-839-372-448-321-568
Capex -301-491-807-763-734-659-424-442-316-554
Net Investments -840-140-18648-7-7-20
Others 21-7722375125
Cash Flow From Financing Activity -224-12950359155-597-217-262-438444
Net Proceeds from Shares 000007340000
Net Proceeds from Borrowing -39-55000000000
Interest Paid -5-5-26-70-111-73-52-50-49-79
Dividend Paid -79-90-91-91-3260-275-197-157-216
Others -101-29120220592-1,259110-16-231739
Net Cash Flow 417-286-69115-12827-371445-37

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)58.0223.2520.422426.9726.9110.117.1213.411.63
ROCE (%)65.8628.8722.1522.6623.326.2811.257.4413.4213.51
Asset Turnover Ratio1.411.150.910.870.830.820.750.8510.95
PAT to CFO Conversion(x)1.320.810.741.370.561.311.062.121.30.15
Working Capital Days
Receivable Days41405047544140606166
Inventory Days55708079859010610091108
Payable Days197219259258223188174148151164

Alembic Pharmaceuticals Ltd Stock News

Alembic Pharmaceuticals Ltd FAQs

The current trading price of Alembic Pharma on 05-Dec-2025 15:31 is ₹902.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Alembic Pharma stood at ₹17,733.9.
The latest P/E ratio of Alembic Pharma as of 04-Dec-2025 is 39.94.
The latest P/B ratio of Alembic Pharma as of 04-Dec-2025 is 3.37.
The 52-week high of Alembic Pharma is ₹1,122.4 and the 52-week low is ₹725.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Alembic Pharma is ₹6,267 ( Cr.) .

About Alembic Pharmaceuticals Ltd

The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India. The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last century.

With an emphasis on innovation and technology, the company has established a state-of-the-art research facility - Alembic Research Centre (ARC)-including formulation research, and huge bioequivalence facility at Vadodara, Gujarat. Additionally, APL has recently invested in ultra-modern R&D center at Hyderabad.

Business area of the company

The company is principally engaged in the manufacturing and selling of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments.

Awards and recognition

  • Forbes India Awards Mr Pranav Amin and Mr. Shaunak Amin as ‘NextGen Entrepreneurs of the Year’
  • 1st Runner up Position in Job Safety Analysis(JSA) - at CII Industrial Safety Summit 2016
  • The company’s Commitment towards Risk Management honoured at Gujarat Seminar and Conclave on Risk Management.
  • The company’s MDs honoured with 'Transformational Leader Award'
  • The company won 'HR event of the Year' and 'Outstanding contribution to the cause of Education' at the 'Gujarat Best Employer Brand Awards 2017'
  • The company won 'HR event of the Year' at the 'Gujarat Best Employer Brand Awards 2017'

Milestones

  • 1907: Started manufacturing tinctures and alcohol at Vadodara.
  • 1940: Started manufacturing cough syrup, vitamins, tonics and sulphur drugs.
  • 1961: Lal bahadur Shastri inaugurates the Penicillin plant.
  • 1967: Bulk manufacturing of Vitamin B12.
  • 1971: Erythromycin manufactured for the first time in India.
  • 1972: Althrocin a brand of Erythromycin launched.
  • 1997: Althrocin becomes top selling brand in India.
  • 1999: Alembic starts production of synthetic organic API.
  • 2000: Gets ISO 14000 certification for its facilities at Vadodara.
  • 2001: Starts manufacturing of Cephalosporin C.
  • 2007: Acquisition of non - oncology business of Dabur Pharma Ltd.
  • 2009: Addressed chronic therapies through multiple marketing divisions.
  • 2010: ANDA’s total filed 38. DMF total filed to 53 and get approval for 15.
  • 2011: Pharmaceutical Business demerged from Alembic - APL Listed.
  • 2012: Launched Dermatology division in domestic market with 8 products.
  • 2013: Launched first NDA with a partner. Commenced filing in EU, Australia and Brazil.
  • 2014: Formed a JV in Algeria- Alembic MAMI SPA to explore African market.
  • 2015: Launched Aripiprazole on Day-1. Established the U. S front-end, transition to own marketing in the U.S.
  • 2016: Formed JV 60:40 with Orbicular - “Aleor Dermaceuitical Limited” for developing Dermatology Products for international markets.
  • 2017: Shri. Vijay Rupani - Hon’ble Chief Minister of Gujarat, inaugurates the manufacturing facility for Oncology medicines (oral solids and liquid injectable vials).
  • 2017: Acquired Orit Laboratories LLC, USA.
  • 2018: FDA approved Aleor’s dermatology facility.
  • 2018: Highest ever investment commitment across four new manufacturing facilities.
  • 2019: FDA approves Oncology oral solid facility.
  • 2019: Formed a JV, to enter China.
  • 2020: US front-end achieved milestone of $ 250 Mn Sales in 2019-20.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×